Sign In
Buy ARVN
$7.70
-0.300 (-3.75%)
At Close: Jun 03, 2026
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
04:30pm, Wednesday, 24'th Apr 2024
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann
Arvinas inks over $1.0 billion deal with Novartis
11:31am, Thursday, 11'th Apr 2024
Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 millio
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 bill
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
09:51am, Tuesday, 09'th Apr 2024
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
04:40pm, Monday, 18'th Mar 2024
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - - Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -
Arvinas to Participate in Upcoming Investor Conferences
07:00am, Monday, 04'th Mar 2024
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
09:31am, Wednesday, 28'th Feb 2024
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
09:31am, Tuesday, 27'th Feb 2024
Arvinas, Inc. (ARVN) came out with a quarterly loss of $2.53 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.56 per share a year ago.
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
07:00am, Tuesday, 27'th Feb 2024
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and th
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
10:56am, Friday, 23'rd Feb 2024
The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?
01:01pm, Wednesday, 21'st Feb 2024
Does Arvinas, Inc. (ARVN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Arvinas Announces Chief Financial Officer Transition
04:05pm, Tuesday, 20'th Feb 2024
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn.
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
07:00am, Tuesday, 20'th Feb 2024
– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) –
Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet
10:56am, Tuesday, 06'th Feb 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the
Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?
04:01am, Friday, 02'nd Feb 2024
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down t
